NCT04203680View on ClinicalTrials.gov

Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

December 25, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

April 25, 2020

Conditions
Cardioplegia Solution Adverse Reaction
Interventions
DRUG

HTK cardioplegic solution

30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg

DRUG

blood cardioplegia

one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins

Trial Locations (2)

11566

Ain Shams university, Cairo

Unknown

Ain Shams university, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04203680 - Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG | Biotech Hunter | Biotech Hunter